Circulating CEA levels in patients with fulminant hepatitis

Area of Science:

• Hepatology
• Clinical Chemistry
• Oncology Biomarkers

Background:

• Fulminant hepatitis is a severe liver condition with high mortality.
• Carcinoembryonic Antigen (CEA) is a tumor marker often elevated in cancers, including liver metastases.
• The behavior of CEA in non-malignant severe liver disease is not well-characterized.

Purpose of the Study:

• To investigate Carcinoembryonic Antigen (CEA) levels in patients with fulminant hepatitis.
• To compare CEA levels in fulminant hepatitis to those typically observed in hepatic metastases.
• To explore potential correlations between CEA levels and clinical/pathological findings in fulminant hepatitis.

Main Methods:

• Blood specimens were collected from 14 patients diagnosed with fulminant hepatitis.
• Carcinoembryonic Antigen (CEA) levels were quantified using immunoassay techniques.
• CEA levels were analyzed in relation to prognosis, liver chemistries, and postmortem histopathology.

Main Results:

• Elevated CEA levels (1.9-21 ng/ml, mean 7.0 ng/ml) were observed in most patients with fulminant hepatitis.
• CEA levels were generally lower than those typically found in hepatic metastases.
• No significant correlation was found between CEA levels and prognosis, liver function tests, or histopathology.

Conclusions:

• Patients with fulminant hepatitis frequently exhibit increased circulating CEA levels.
• Elevated CEA in this context is likely due to impaired hepatic clearance rather than malignancy.
• CEA levels in fulminant hepatitis are considerably lower than those associated with hepatic metastases.